Literature DB >> 14832975

Erythema multiforme exudativum major (Stevens-Johnson syndrome).

D W ASHBY, T LAZAR.   

Abstract

Entities:  

Keywords:  STEVENS-JOHNSON SYNDROME

Mesh：

Year:  1951        PMID： 14832975     DOI： 10.1016/s0140-6736(51)92611-6

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  13 in total

1.  Erythema multiforme and nephritis.

Authors:  J S COMAISH; D N KERR
Journal:  Br Med J       Date:  1961-07-08

2.  [The Stevens-Johnson syndrome; case reports, attempts at clarification of etiology, relation to virus diseases].

Authors:  P JORDAN; R BURKHARDT; T NASEMANN
Journal:  Arch Klin Exp Dermatol       Date:  1957

3.  Cortisone in the treatment of the oculo-mucous membrane (Stevens-Johnson) syndrome.

Authors:  B SHALLARD; J M LAYING
Journal:  Can Med Assoc J       Date:  1954-07       Impact factor: 8.262

4.  Pulmonary thromboembolism in erythema multiforme.

Authors:  S M Santiago; W B Klaustermeyer; G Brockman
Journal:  West J Med       Date:  1977-06

Review 5.  Stevens-Johnson syndrome: a review of the literature.

Authors:  V J Stitt
Journal:  J Natl Med Assoc       Date:  1988-01       Impact factor: 1.798

6.  Life-threatening dermatoses.

Authors:  D L Cram
Journal:  Calif Med       Date:  1973-02

7.  The role of Mycoplasma pneumoniae infection in erythema multiforme.

Authors:  A Lyell; A M Gordon; H M Dick; R G Sommerville
Journal:  Proc R Soc Med       Date:  1968-12-12

Review 8.  Erythema multiforme: clinical spectrum and immunopathogenesis.

Authors:  J A Kazmierowski; K D Wuepper
Journal:  Springer Semin Immunopathol       Date:  1981-06

9.  Erythema multiforme.

Authors: 
Journal:  Br Med J       Date:  1972-01-08

Review 10.  Amniotic membrane transplantation as a new therapy for the acute ocular manifestations of Stevens-Johnson syndrome and toxic epidermal necrolysis.

Authors:  Elizabeth Shay; Ahmad Kheirkhah; Lingyi Liang; Hossam Sheha; Darren G Gregory; Scheffer C G Tseng
Journal:  Surv Ophthalmol       Date:  2009-08-21       Impact factor: 6.048
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.